Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 6/20 | 0.75 |
| ▸ | PDE4B | Q07343 | 6/20 | 0.75 |
| ▸ | PDE4C | Q08493 | 6/20 | 0.75 |
| ▸ | PDE4D | Q08499 | 6/20 | 0.75 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | TNF | P01375 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4850929 | 0.91 | PDE4A (0.62) | PDE4APDE4BPDE4CPDE4DMEN1 | |
| SCHEMBL825613 | 0.90 | PDE4A (0.63) | PDE4APDE4BPDE4CPDE4DMEN1 | |
| SCHEMBL5905281 | 0.90 | PDE4A (0.69) | PDE4APDE4BPDE4CPDE4DMEN1 | |
| SCHEMBL5941294 | 0.90 | TNF (0.69) | PDE4APDE4BPDE4CPDE4DMEN1 | |
| SCHEMBL6703914 | 0.90 | TNF (0.69) | PDE4APDE4BPDE4CPDE4DMEN1 | |
| SCHEMBL4445016 | 0.90 | TNF (0.69) | PDE4APDE4BPDE4CPDE4DMEN1 | |
| SCHEMBL4919222 | 0.87 | PDE4A (0.60) | PDE4APDE4BPDE4CPDE4DMEN1 | |
| SCHEMBL4637167 | 0.86 | PDE4A (1.00) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL4637688 | 0.85 | PDE4A (0.98) | PDE4APDE4BPDE4CPDE4DTNF | |
| SCHEMBL6099978 | 0.85 | PDE4A (0.71) | PDE4APDE4BPDE4CPDE4DMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7091356-B2 | Substituted alkanohydroxamic acids and method of reducing TNFα levels | CELGENE CORPORATION | 2006-08-15 | — | — | US | disclosed |
| US-20040006096-A1 | Substituted alkanohydroxamic acids and method of reducing TNFalpha levels | CELGENE CORPORATION | 2004-01-08 | — | — | US | disclosed |
| US-6656964-B2 | Reducing levels of tumor necrosis factor alpha; inhibition of undesireable levels of matrix metalloproteinases | CELGENE CORPORATION | 2003-12-02 | — | — | US | disclosed |
| EP-1035848-B1 | SUBSTITUTED ALKANOHYDROXAMIC ACIDS AND METHOD OF REDUCING TNF-ALPHA LEVELS | CELGENE CORP (US) | 2003-04-23 | — | — | EP | disclosed |
| US-20010049371-A1 | Method of inhibiting phosphodiesterases with substituted alkanohydroxamic acids | CALGENE CORPORATION | 2001-12-06 | — | — | US | disclosed |
| US-6214857-B1 | REDUCES TUMOR NECROSIS FACTOR LEVELS | CELGENE CORPORATION | 2001-04-10 | — | — | US | disclosed |
| CN-1265590-A | Substituted alkanohydroxamic acid and method of reducing TNF 'alpha' levels | CELGENE CORP (US) | 2000-09-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006096-A1 | Substituted alkanohydroxamic acids and method of reducing TNFalpha levels | TNF, TNFRSF1A, LTA | PDE4A 10/4885PDE4B 54/4885PDE4C 37/4885 |
| US-20010049371-A1 | Method of inhibiting phosphodiesterases with substituted alkanohydroxamic acids | PDE3A, PDE2A, PDE3B | PDE4A 6/4885PDE4B 15/4885PDE4C 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.